文献速递慢阻肺

β2肾上腺素能受体基因型与COPD严重急性加重风险:前瞻性队列研究

β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study.
PubMed 文献 · Thorax · 2019-09-03

在哥本哈根普通人群研究中,5262例COPD患者接受β2肾上腺素能受体基因Gly16Arg和Gln27Glu分型,随访5年(平均3.4年)记录461次严重急性加重。与16Gly纯合子相比,16Gly/Arg杂合子和16Arg纯合子的严重急性加重风险分别升高(HR 1.62和1.41);与27Glu纯合子相比,27Gln/Glu杂合子和27Gln纯合子风险也升高(HR 1.35和1.49)。CCHS 923例COPD复制分析呈类似趋势。

要点

  • β2肾上腺素能受体常见基因型与COPD严重急性加重风险相关
  • 16Arg等位基因(rs1042713)可能为主要遗传影响因素
  • 27Gln纯合子中16Arg携带者风险显著增高

核心结论

  • 常见β2肾上腺素能受体基因型影响COPD严重急性加重风险,可能主要归因于rs1042713的16Arg等位基因的遗传影响。

研究设计与样本

  • 前瞻性队列研究:哥本哈根普通人群研究中96 762人里识别5262例COPD(FEV1/FVC<0.7、FEV1<预计值80%、年龄>40岁、无哮喘)并完成基因分型。
  • 严重急性加重定义为随访5年(平均3.4年)内因COPD急性入院。
  • 复制分析使用哥本哈根城市心脏研究(CCHS)中923例同样诊断的COPD患者。

主要发现

  • 5262例COPD患者共记录461次严重急性加重。
  • 与16Gly纯合子相比,16Gly/Arg杂合子HR 1.62(95%CI 1.30–2.03,p=0.00002),16Arg纯合子HR 1.41(95%CI 1.04–1.91,p=0.03)。
  • 与27Glu纯合子相比,27Gln/Glu杂合子HR 1.35(95%CI 1.03–1.76,p=0.03),27Gln纯合子HR 1.49(95%CI 1.12–1.98,p=0.006)。
  • CCHS复制分析呈类似趋势。
  • 仅在27Gln纯合子中,与16Gly纯合子相比,16Gly/Arg杂合子HR 5.20(95%CI 1.81–14.9,p=0.002),16Arg纯合子HR 4.03(95%CI 1.40–11.6,p=0.01)。

临床怎么用

  • 对于COPD患者,可关注β2肾上腺素能受体rs1042713和rs1042714基因型以辅助评估严重急性加重风险。
  • 16Arg等位基因携带者(尤其27Gln纯合子背景)可能需更密切随访和加重预防管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individual susceptibility to exacerbations in chronic obstructive pulmonary disease (COPD) is likely influenced by genetic factors; however, most such variance is unexplained. We hypothesised that β2-adrenergic receptor genotypes, Gly16Arg (rs1042713, c.46G>A) and Gln27Glu (rs1042714, c.79C>G) influence risk of severe exacerbations in COPD. METHODS: Among 96 762 individuals in the Copenhagen General Population Study, we identified 5262 with COPD (forced expiratory volume in one second divided by forced vital capacity, FEV1/FVC, below 0.7, FEV1 less than 80% of predicted value, age above 40 years and no asthma) who had genotyping performed. Severe exacerbations were defined as acute admissions due to COPD during 5 years of follow-up (mean 3.4 years). 923 individuals with COPD diagnosed similarly in the Copenhagen City Heart Study (CCHS) were used for replication analyses. RESULTS: We recorded 461 severe exacerbations in 5262 subjects. The HRs for severe exacerbations were 1.62 (95% CI 1.30 to 2.03, p=0.00002) for 16Gly/Arg heterozygotes and 1.41 (1.04 to 1.91, p=0.03) for 16Arg homozygotes, compared with 16Gly homozygotes. HRs were 1.35 (1.03 to 1.76, p=0.03) for 27Gln/Glu heterozygotes and 1.49 (1.12 to 1.98, p=0.006) for 27Gln homozygotes, compared with 27Glu homozygotes. Similar trends were observed in the CCHS. Among 27Gln homozygotes only, HRs were 5.20 (1.81 to 14.9, p=0.002) for 16Gly/Arg heterozygotes and 4.03 (1.40 to 11.6, p=0.01) for 16Arg homozygotes, compared with 16Gly homozygotes. CONCLUSION: Common β2-adrenergic receptor genotypes influence risk of severe exacerbations in COPD, potentially mainly by genetic influence of the 16Arg allele in rs1042713.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Ingebrigtsen TS, Vestbo J, Rode L, et al. β2-Adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study. Thorax. 2019. PMID: 31481635. doi:10.1136/thoraxjnl-2018-212340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。